Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Emrusolmin by Teva Pharmaceutical Industries for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration): Likelihood of Approval
Emrusolmin is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Multiple System Atrophy (MSA or...
TEV-56278 by Teva Pharmaceutical Industries for Solid Tumor: Likelihood of Approval
TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor. According to GlobalData,...
TEV-56192 by Teva Pharmaceutical Industries for Unspecified Neurologic Disorders: Likelihood of Approval
TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Neurologic Disorders. According to...
TEV-56192 by Teva Pharmaceutical Industries for Unspecified Immunological Disorders: Likelihood of Approval
TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Immunological Disorders. According to...
Deutetrabenazine by Teva Pharmaceutical Industries for Dystonia: Likelihood of Approval
Deutetrabenazine is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Dystonia. According to GlobalData, Phase...
Omacetaxine mepesuccinate by Teva Pharmaceutical Industries for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Omacetaxine mepesuccinate is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Relapsed Acute Myeloid Leukemia....
Omacetaxine mepesuccinate by Teva Pharmaceutical Industries for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Omacetaxine mepesuccinate is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Refractory Acute Myeloid Leukemia....
CEP-11981 by Teva Pharmaceutical Industries for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
CEP-11981 by Teva Pharmaceutical Industries for Adenocarcinoma: Likelihood of Approval
CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase...
Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of Approval
Olanzapine ER is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Schizophrenia. According to GlobalData,...
Omalizumab biosimilar by Teva Pharmaceutical Industries for Chronic Urticaria Or Hives: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Chronic Urticaria Or Hives....
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Omalizumab Biosimilar?
Omalizumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Chronic Urticaria...
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Denosumab Biosimilar?
Denosumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Post Menopausal...
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Wet (Neovascular...